Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Text search

Sort by Random

Display 15 Products per page

Rebinyn
Read More
Rebinyn is a glycoPEGylated rebombinant factor IX (rfIX) therapy developed by Novo Nordisk for the treatment of hemophilia B.
May 20, 2018
Find out more
Tykerb
Read More
Tykerb (lapatinib; Novartis) is an orally available EGFR (epidermal growth factor receptor) and human epidermal growth factor receptor 2 (HER2) dual tyrosine kinase inhibitor.
March 9, 2015
Find out more
ralinepag
Read More
Ralinepag (Arena Pharmaceuticals/Everest Medicines) is a selective prostaglandin I2 receptor agonist. PGI2 agonists are potent vasodilators and platelet aggregation inhibitors, which also help relax smooth muscle cells by counteracting the effect of vasoconstrictive mediators.
October 29, 2018
Find out more
Isatuximab
Read More
Isatuximab (Sanofi/ImmunoGen) is a humanized monoclonal antibody which targets cancer cells expressing the transmembrane glycoprotein CD38, which is highly expressed on malignant multiple myeloma (MM) cells, but at low levels in other tissues.
August 9, 2018
Find out more
Ozanimod
Read More
Ozanimod (Celgene) is a sphingosine 1-phosphate (S1P) receptor agonist, with selectivity for the sphingosine 1-phosphate type 1 receptor (S1P1) and sphingosine 1-phosphate 5 receptor (S1P5).
August 2, 2018
Find out more
Flucelvax QIV
Read More
Flucelvax is an inactivated subunit cell-based QIV that contains antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination.
January 10, 2019
Find out more
Viekira Pak franchise
Read More
AbbVie’s Viekira Pak franchise comprises Viekira Pak ([paritaprevir + ritonavir + ombitasvir] + dasabuvir), Viekira XR ([paritaprevir + ritonavir + ombitasvir + dasabuvir]), and Technivie ([paritaprevir + ritonavir + ombitasvir]), which is branded as Viekirax outside the US market.
November 6, 2017
Find out more
Abemaciclib
Read More
Abemaciclib is a small molecule inhibitor of cyclin-dependent kinase (CDK)4 and CDK6 in Phase III development for non-small cell lung cancer and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer by Eli Lilly
November 14, 2016
Find out more
Cenicriviroc
Read More
Cenicriviroc (Allergan/Takeda) is a potent immunomodulator that blocks the chemokine receptors-2/5 (CCR-2/5). CCR-2/5 have been linked to the inflammatory and fibrogenic pathways in non-alcoholic steatohepatitis (NASH), and by inhibiting CCR-2/5 it is anticipated that cenicriviroc will reduce inflammation and fibrosis.
July 22, 2019
Find out more
Neupro
Read More
Neupro (UCB/Otsuka) is a transdermal formulation of the non-ergoline dopamine receptor agonist rotigotine. Applied once daily, the patch allows continuous drug administration over 24 hours and avoids the fluctuation in dopaminergic stimulation resulting from numerous oral doses
June 21, 2018
Find out more
Ketek
Read More
Ketek (telithromycin; Sanofi) is an oral semisynthetic antibacterial agent of the ketolide class. The drug, which is the first ketolide to gain regulatory approval for the treatment of community-acquired pneumonia, is structurally related to the macrolide class of antibiotics.
June 19, 2015
Find out more
Lupron
Read More
Lupron (leuprolide; Takeda/AbbVie) is a gonadotropin-releasing hormone (GnRH) agonist which acts on the pituitary gland in the brain to stimulate luteinizing hormone (LH) release, resulting in a temporary surge in serum testosterone levels known as “flare.”
January 18, 2018
Find out more
Tecentriq
Read More
Tecentriq (atezolizumab; Roche/Chugai) is an antibody designed to target programmed death-ligand 1 (PD-L1) on tumor cells, allowing the body’s immune system to recognize and properly respond to the tumor.
February 26, 2020
Find out more
Nucala
Read More
Nucala (mepolizumab; GlaxoSmithKline) is a humanized monoclonal immunoglobulin G1 antibody that binds to interleukin (IL)-5, which plays a significant role in the activation, proliferation, and differentiation of eosinophils.
July 31, 2018
Find out more
MenABCW-135Y
Read More
GlaxoSmithKline’s MenABCW-135Y is a pentavalent meningococcal conjugate vaccine for the A, B, C, W-135, and Y meningococcal strains. With all of the vaccine’s announced Phase II trials now complete, Datamonitor Healthcare expects that Phase III trials could start by the end of 2019, and forecasts US and EU approvals in adolescents and adults to occur as early as 2022.
September 3, 2019
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *